

File No. 250725

Committee Item No. 7

Board Item No. _____

COMMITTEE/BOARD OF SUPERVISORS

AGENDA PACKET CONTENTS LIST

Committee: Budget and Finance Committee Date July 23, 2025

Board of Supervisors Meeting Date _____

Cmte Board

- | | | |
|-------------------------------------|--------------------------|--|
| ☐ | ☐ | Motion |
| ☒ | ☐ | Resolution |
| ☐ | ☐ | Ordinance |
| ☐ | ☐ | Legislative Digest |
| ☐ | ☐ | Budget and Legislative Analyst Report |
| ☐ | ☐ | Youth Commission Report |
| ☐ | ☐ | Introduction Form |
| ☒ | ☐ | Department/Agency Cover Letter and/or Report |
| ☐ | ☐ | MOU |
| ☒ | ☐ | Grant Information Form |
| ☒ | ☐ | Grant Budget |
| | | • Budget Justification Year 3 |
| | | • Budget vs. Actual by Project |
| ☐ | ☐ | Subcontract Budget |
| ☐ | ☐ | Contract/Agreement |
| ☐ | ☐ | Form 126 – Ethics Commission |
| ☒ | ☐ | Award Letter |
| ☒ | ☐ | Application |
| ☐ | ☐ | Public Correspondence |

OTHER (Use back side if additional space is needed)

- | | | |
|-------------------------------------|--------------------------|---|
| ☒ | ☐ | <u>Modification No. 1 5/17/2024</u> |
| ☒ | ☐ | <u>Modification No. 2 5/12/2025</u> |
| ☒ | ☐ | <u>Reimbursement Subaward 6/7/2023</u> |
| ☒ | ☐ | <u>DPH Statement on Retroactivity 7/17/2025</u> |
| ☒ | ☐ | <u>DPH Presentation 7/23/2025</u> |
| ☐ | ☐ | _____ |
| ☐ | ☐ | _____ |
| ☐ | ☐ | _____ |
| ☐ | ☐ | _____ |
| ☐ | ☐ | _____ |

Completed by: Brent Jalipa Date July 17, 2025

Completed by: Brent Jalipa Date _____

1 [Accept and Expend Grant - Retroactive - National Institutes of Health - Fred Hutchinson
2 Cancer Center - Statistical Methods for Advancing HIV Prevention - \$105,832]

3 **Resolution retroactively authorizing the Department of Public Health to accept and**
4 **expend a grant from the National Institutes of Health through Fred Hutchinson Cancer**
5 **Center for participation in a program, entitled “Statistical Methods for Advancing HIV**
6 **Prevention,” in the amount of \$105,832 for the period of March 1, 2023, through**
7 **February 28, 2026.**

8
9 WHEREAS, The National Institutes of Health (NIH), through Fred Hutchinson Cancer
10 Center (FHCC) as a pass-through entity, has agreed to fund the Department of Public Health
11 (DPH) in the amount of \$105,832 for participation in a program, entitled “Statistical Methods
12 for Advancing HIV Prevention,” for the period of March 1, 2023, through February 28, 2026;
13 and

14 WHEREAS, This funding allows for DPH to provide scientific guidance in developing
15 and testing the safety and efficacy of vaccine interventions designed to prevent the
16 transmission of human immunodeficiency virus (HIV); and

17 WHEREAS, The grant does not require an Annual Salary Ordinance Amendment; and

18 WHEREAS, A request for retroactive approval is being sought because DPH received
19 the original grant award on June 7, 2023, for a project start date of March 1, 2023, in the
20 amount of \$34,540, then received an increase in grant funds on May 17, 2024, in the amount
21 of \$35,965 for a total amount of \$70,505 for a project start date of March 1, 2024, and finally
22 received another increase in grant funds on May 12, 2025, in the amount of \$35,327 for a total
23 amount of \$105,832, for a project start date of March 1, 2025, through February 28, 2026; and

24 WHEREAS, The grant budget includes a provision for indirect costs in the amount of
25 \$20,436; now, therefore, be it

1 RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant
2 in the amount of \$105,832 from the NIH through FHCC for participation in a program, entitled
3 “Statistical Methods for Advancing HIV Prevention,” for the period of March 1, 2023, through
4 February 28, 2026; and, be it

5 FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and
6 expend the grant funds pursuant to Administrative Code, Section 10.170-1; and, be it

7 FURTHER RESOLVED, That the Director of Health is authorized to enter into the
8 Grant Agreement on behalf of the City; and, be it

9 FURTHER RESOLVED, That within thirty (30) days of the Grant Agreement being fully
10 executed by all parties, the Director of Health shall provide a copy to the Clerk of the Board of
11 Supervisors for inclusion in the official file.

1 Recommended:
2
3 _____ /s/ _____

Approved: _____ /s/ _____
Mayor

4 Daniel Tsai
5 Director of Health
6
7
8
9

Approved: _____ /s/ _____
Controller

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

File Number: 250725
(Provided by Clerk of Board of Supervisors)

Grant Resolution Information Form
(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: **Statistical Methods for Advancing HIV Prevention**
2. Department: **Department of Public Health
Population Health Division**
3. Contact Person: **Susan Buchbinder** Telephone: **415-437-7479**
4. Grant Approval Status (check one):

☒ Approved by funding agency

☐ Not yet approved

5. Amount of Grant Funding Approved or Applied for: **\$105,832**
(Year 1 March 01, 2023 – February 29, 2024: \$34,540
Year 2 March 01, 2024 – February 28, 2025: \$35,965
Year 3 March 01, 2025 – February 28, 2026: \$35,327

6a. Matching Funds Required: **\$0**

b. Source(s) of matching funds (if applicable): **N.A.**

7a. Grant Source Agency: **National Institutes of Health**

b. Grant Pass-Through Agency (if applicable): **Fred Hutchinson Cancer Center**

8. Proposed Grant Project Summary:

On this project, the Department of Public Health (DPH) will help to identify logistical/implementation and clinical issues pertinent to evaluating Human Immunodeficiency Virus (HIV) incidence with recency testing data, and clinical considerations pertinent to trial design and efficacy evaluation. DPH will provide collaboration and input on the application of these approaches to existing datasets. DPH will assist in the dissemination and application of the proposed methods to future HIV prevention trials.

9. Grant Project Schedule, as allowed in approval documents, or as proposed:

Start-Date: **March 1, 2023**

End-Date: **February 28, 2026**

10a. Amount budgeted for contractual services: **\$0**

b. Will contractual services be put out to bid? **N.A.**

c. If so, will contract services help to further the goals of the Department's Local Business Enterprise (LBE) requirements? **N.A.**

d. Is this likely to be a one-time or ongoing request for contracting out? **N.A.**

11a. Does the budget include indirect costs? ☒ Yes ☐ No

b1. If yes, how much? **\$20,436**

b2. How was the amount calculated? **23.93% of Salaries and Fringe Benefits**

c1. If no, why are indirect costs not included? **N.A.**

☐ Not allowed by granting agency

☐ To maximize use of grant funds on direct services

☐ Other (please explain):

c2. If no indirect costs are included, what would have been the indirect costs? **N.A.**

12. Any other significant grant requirements or comments:

The grant does not require an ASO amendment and partially reimburses the department for the existing position:

No.	Class	Job Title	FTE	Start Date	End Date
1	2233	Supervising Physician Specialist	0.100	03/01/2025	02/28/2026

We respectfully request for approval to accept and expend these funds retroactive to March 1, 2023. The Department received the grant increase of \$35,965 on May 17, 2024, and another grant increase of \$35,327 on May 12, 2025, for a total of \$105,832 for the period of March 1, 2023, to February 28, 2026. The AL # for this grant is 93.855.

Project Description: HD HIV PD200 2526 Statistical

Project ID: 10041908

Proposal ID: CTR00004537

Fund ID: 11580

Version ID: V101

Authority ID: 10001

Activity ID: 0001

****Disability Access Checklist** (Department must forward a copy of all completed Grant Information Forms to the Mayor's Office of Disability)**

13. This Grant is intended for activities at (check all that apply):

- | | | |
|--|---|--|
| ☒ Existing Site(s) | ☐ Existing Structure(s) | ☐ Existing Program(s) or Service(s) |
| ☐ Rehabilitated Site(s) | ☐ Rehabilitated Structure(s) | ☐ New Program(s) or Service(s) |
| ☐ New Site(s) | ☐ New Structure(s) | |

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;
2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;
3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor's Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:

Comments:

Departmental ADA Coordinator or Mayor's Office of Disability Reviewer:

Toni Rucker, PhD
(Name)

DPH ADA Coordinator
(Title)

Date Reviewed: 6/6/2025 | 10:31 AM PDT

DocuSigned by:
Toni Rucker
(Signature Required)

Department Head or Designee Approval of Grant Information Form:

Daniel Tsai
(Name)

Director of Health
(Title)

Date Reviewed: 6/16/2025 | 11:26 AM PDT

Signed by:
Jenny Louie for Daniel Tsai
(Signature Required)

Grant Increases:



**National Institutes of Health - Fred Hutchinson
Cancer Center - Statistical Methods for Advancing
HIV Prevention**

**National Institutes of Health - Family Health
International - HIV Prevention Trials Network**

BOS Budget & Finance Committee

Dr. Susan Buchbinder, Director, Bridge HIV, Population Health Division

July 23, 2025

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

Overview of File 250725



National Institutes of Health - Fred Hutchinson Cancer Center - Statistical Methods for Advancing HIV Prevention

- **Amount:** \$105,832
- **Timeline:** March 1, 2023 – February 28, 2026
- **Grantor:** National Institutes of Health through Fred Hutchinson Cancer Center
- **Grant Summary:** Supports DPH's participation in the Statistical Methods for Advancing HIV Prevention Program
 - Provide scientific guidance in developing statistical methods for testing the safety and efficacy of vaccine interventions designed to prevent the transmission of human immunodeficiency virus (HIV)

Retroactivity



We are seeking **retroactive authorization** to accept this grant increase.

- The initial project period for this grant began on March 1, 2023.
- DPH received several grant increases for this grant.
- SFDPH received notice of the most recent grant increase on May 12, 2025, for a project start date of March 1, 2025.
- DPH brought this item to the BOS after going through the fiscal approvals process, including Controller's Office review and approval.

Overview of File 250743



National Institutes of Health - Family Health International - HIV Prevention Trials Network:

- **Amount:** \$108,968
- **Timeline:** April 1, 2024 – November 30, 2025
- **Funder:** National Institutes of Health, through Family Health International
- **Grant Summary:** support DPH's participation in the HIV Prevention Trials Network (HPTN)
 - Adapt and test a suite of health tools to increase HIV pre-exposure prophylaxis (PrEP) and STI post-exposure prophylaxis (DoxyPEP) uptake and adherence among young Latino gay, bisexual, and other cis-gender MSM

Retroactivity



We are seeking **retroactive authorization** to accept this grant increase.

- The initial project period for this grant began on April 1, 2024.
- DPH received several grant increases for this grant.
- SFDPH received notice of the most recent grant increase on April 17, 2025, for a project start date of March 1, 2025.
- DPH brought this item to the BOS after going through the fiscal approvals process, including Controller's Office review and approval.



Conclusion

DPH respectfully requests retroactive approval of these items. Thank you!

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH
Population Health Division
Statistical Methods for Advancing HIV Prevention
March 1, 2023 - February 28, 2026

		Year 1 Project: 10040358 3/1/23 - 2/29/24	Year 2 Project: 10041201 3/1/24 - 2/28/25	Year 3 Project: 10041908 3/1/25 - 2/28/26	Total Amount
	Personnel -				-
	Supervising Physician Specialist	20,370	21,210	22,190	63,770
					-
					-
	Fringe benefits	7,333	7,636	6,657	21,626
					-
	Travel				-
					-
	Contractual				-
					-
					-
	Indirect Costs	6,837	7,119	6,480	20,436
Total		34,540	35,965	35,327	105,832

BUDGET JUSTIFICATION
City and County of San Francisco – San Francisco Department of Public Health
March 1, 2025 – February 28, 2026

CCSF-SFDPH will enter into a consortium arrangement with FHRC.

	<u>Direct</u>	<u>Indirect</u>	<u>Total Cost</u>
Year 03:	\$28,847	\$6,480	\$35,327

Key Personnel

Susan Buchbinder, MD., co-Investigator (1.2 calendar months, Years 3). Dr. Buchbinder is the Director of Bridge HIV, a prevention research unit in the San Francisco Department of Public Health and Clinical Professor of Medicine, Epidemiology and Biostatistics at the University of California, San Francisco. She has been leading multi-site efforts to understand risk factors for HIV infection and conduct HIV prevention intervention trials for over 30 years. She has led pivotal studies in the HIV vaccine and prevention fields, served in leadership positions in the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN), led one of the highest capacity US sites for enrolling diverse cohorts of HIV negative at-risk persons, co-founded the San Francisco Getting to Zero Consortium, and mentored a large and diverse pool of early stage investigators. Most recently, she is protocol chair of the Phase 3 HVTN 706 (Mosaico) Phase 3 vaccine efficacy trial, and co-chair of the Phase 2b HVTN 705 (Imbokodo) vaccine efficacy trial. She has been an investigator in numerous other efficacy trials, including iPrEx, HPTN 083, Impower, and PURPOSE 2. Together with Dr. Holly Janes, she has co-chaired the Efficacy Trials Working Group of the HVTN for the past 11 years. She co-chairs the Integrated Strategies Working Group of the HPTN, which plans for efficacy and implementation science trials of non-vaccine prevention interventions. On this project, Dr. Buchbinder will serve as a clinical expert. She will help to identify logistical/implementation and clinical issues pertinent to evaluating HIV incidence with recency testing data (Specific Aim 1), and clinical considerations pertinent to trial design and efficacy evaluation under Specific Aim 2. She will provide collaboration and input on the application of these approaches to existing datasets. She will assist in the dissemination and application of the proposed methods to future HIV prevention trials.

BENEFITS

CCSF-SFDPH has and uses a mandatory 30% fringe benefits rate.

FACILITIES & ADMINISTRATIVE COSTS

CCSF-SFDPH F&A rate is 22.462% of total personnel cost.

Per the NIH, Grant Policy Statement, Section 7.4 state:

7.4. https://grants.nih.gov/grants/policy/nihgps/HTML5/section_7/7.4_reimbursement_of_facilities_and_administrative_costs.htm

Once NIH awards a grant, it is not obligated to make any supplemental or other award for additional [F&A costs](#) or for any other purpose. There are limited circumstances under which the GMO may award [F&A costs](#) where none were previously awarded or may increase the amount previously awarded. If an award does not include an amount for [F&A costs](#) because the applicant or recipient did not submit a timely [F&A cost](#) proposal and the recipient subsequently establishes a rate, the GMO may amend the award to provide an appropriate amount for [F&A costs](#) if the amendment can be made using funds from the same Federal fiscal year in which the award was made. However, the amount will be limited to the [F&A costs](#) applicable to the period after the date of the recipient's [F&A cost](#) proposal submission. This provision does not affect local governmental agencies that are not required to submit their F&A (indirect) cost proposals to the Federal government. They may charge [F&A costs](#) to NIH grants based on the rate computations they prepare and keep on file for subsequent Federal review.

Budget vs Actual - By Project

Click on amounts to drill to transaction details
Time run: 6/5/2025 1:22:41 PM

Project Code	Project Description	Department Group	Division Code	Division Name	Department Code	Department Description	Fund Code	Fund Description	Authority Code	Authority Description	Account Lvl 3 Description	Account Code	Account Description	Original Budget	Supplemental Budget	Transfer & Other Budget	Carryforward Budget	Revised Budget	GL Actuals	Pre-Encumbrance	Encumbrance	Surplus/Savings (Shortfall/Overspending)	Reserved (Budget)	Available Balance
10001677	HD CH HIV/AIDS	DPH	HPH_PUB_HLTH_DIV	HPH Population Health Division	251929	HPH Community Health	10000	GF Annual Account Ctrl	10000	Operating	City Grant Program	538010	Community Based Org Svcs	\$0	\$0	\$0	\$0	\$0	\$171,000	\$0	\$57,000	(\$228,000)	\$0	(\$228,000)
											Mandatory Fringe Benefits	513010	Retire City Misc	\$165,949	\$0	\$0	\$0	\$165,949	\$264,343	\$0	\$0	(\$98,394)	\$0	(\$98,394)
												514010	Social Security (OASDI & HI)	\$70,300	\$0	\$0	\$0	\$70,300	\$99,109	\$0	\$0	(\$28,809)	\$0	(\$28,809)
												514020	Social Sec-Medicare(HI Only)	\$16,597	\$0	\$0	\$0	\$16,597	\$25,669	\$0	\$0	(\$9,072)	\$0	(\$9,072)
												515010	Health Service-City Match	\$60,116	\$0	\$0	\$0	\$60,116	\$212,358	\$0	\$0	(\$152,242)	\$0	(\$152,242)
												515020	Retiree Health-Match-Prop B	\$8,334	\$0	\$0	\$0	\$8,334	\$15,439	\$0	\$0	(\$7,105)	\$0	(\$7,105)
												515030	RetireeHlthCare-CityMatchPropC	\$3,110	\$0	\$0	\$0	\$3,110	\$2,840	\$0	\$0	\$270	\$0	\$270
												515710	Dependent Coverage	\$121,539	\$0	\$0	\$0	\$121,539	\$4,725	\$0	\$0	\$116,814	\$0	\$116,814
												516010	Dental Coverage	\$11,021	\$0	\$0	\$0	\$11,021	\$13,002	\$0	\$0	(\$1,981)	\$0	(\$1,981)
												519110	Flexible Benefit Package	\$2,743	\$0	\$0	\$0	\$2,743	\$6,485	\$0	\$0	(\$3,742)	\$0	(\$3,742)
												519120	Long Term Disability Insurance	\$4,278	\$0	\$0	\$0	\$4,278	\$3,109	\$0	\$0	\$1,169	\$0	\$1,169
												519130	Life Insurance	\$0	\$0	\$0	\$0	\$0	\$791	\$0	\$0	(\$791)	\$0	(\$791)
											Materials & Supplies	540000	Materials & Supplies-Budget	\$47,038	\$0	\$0	\$0	\$47,038	\$0	\$0	\$0	\$47,038	\$0	\$47,038
												542990	Other Bldg Maint Supplies	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$603	(\$603)	\$0	(\$603)
												543410	Communication Supplies	\$0	\$0	\$0	\$2	\$2	\$1,197	\$0	\$0	(\$1,196)	\$0	(\$1,196)
												549510	Other Office Supplies	\$0	\$0	\$0	\$2,556	\$2,556	\$494	\$0	\$2,506	(\$445)	\$0	(\$445)
												549990	Other Materials & Supplies	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$141	(\$141)	\$0	(\$141)
											Non-Personnel Services	521000	Travel-Budget	\$9,188	\$0	\$0	\$0	\$9,188	\$0	\$0	\$0	\$9,188	\$0	\$9,188
												521020	Travel Costs Paid To Vendors	\$0	\$0	\$0	\$0	\$0	\$80	\$0	\$0	(\$80)	\$0	(\$80)
												521030	Air Travel - Employees	\$0	\$0	\$0	\$0	\$0	\$369	\$0	\$0	(\$369)	\$0	(\$369)
												521050	Non-Air Travel - Employees	\$0	\$0	\$0	\$0	\$0	\$1,941	\$0	\$0	(\$1,941)	\$0	(\$1,941)
												522000	Training - Budget	\$846	\$0	\$0	\$0	\$846	\$0	\$0	\$0	\$846	\$0	\$846
												522010	Training Costs Paid To Empl	\$0	\$0	\$0	\$0	\$0	\$1	\$0	\$0	(\$1)	\$0	(\$1)
												522020	Training Costs Paid To Vendors	\$0	\$0	\$0	\$0	\$0	\$400	\$0	\$0	(\$400)	\$0	(\$400)
												523010	Auto Mileage	\$0	\$0	\$0	\$0	\$0	\$193	\$0	\$0	(\$193)	\$0	(\$193)
												523020	Local Field Exp	\$0	\$0	\$0	\$0	\$0	\$2,272	\$0	\$0	(\$2,272)	\$0	(\$2,272)
												524010	Membership Fees	\$26,800	\$0	\$0	\$0	\$26,800	\$26,247	\$0	\$0	\$553	\$0	\$553
												526990	Other Fees	\$0	\$0	\$0	\$0	\$0	\$8	\$0	\$5	(\$13)	\$0	(\$13)
												527000	Prof & Specialized Svcs-Bdgt	\$17,538,192	\$0	\$0	\$0	\$17,538,192	\$0	\$0	\$0	\$17,538,192	\$0	\$17,538,192
												527890	Other Medical Services	\$575,000	\$0	\$0	\$22,567	\$597,567	\$980,130	\$0	\$2,252,287	(\$2,634,850)	\$0	(\$2,634,850)
												527900	Chn Services	\$115,821	\$0	\$0	\$0	\$115,821	\$0	\$0	\$0	\$115,821	\$0	\$115,821
												527990	Other Professional Services	\$0	\$0	\$0	\$0	\$0	\$3,430,284	\$0	\$8,349,685	(\$11,779,969)	\$0	(\$11,779,969)
												528990	Other Bldg Maint Svcs	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$250	(\$250)	\$0	(\$250)
												529000	Maint Svcs-Equipment-Budget	\$7,520	\$0	\$0	\$0	\$7,520	\$0	\$0	\$0	\$7,520	\$0	\$7,520
												531000	Rents & Leases-Equipment-Bdgt	\$21,620	\$0	\$0	\$0	\$21,620	\$0	\$0	\$0	\$21,620	\$0	\$21,620
												531310	Office Machine Rental	\$0	\$0	\$0	\$52,806	\$52,806	\$33,786	\$0	\$8,619	\$10,401	\$0	\$10,401
												535000	Other Current Expenses - Bdgt	\$135,812	\$0	\$0	\$0	\$135,812	\$0	\$0	\$0	\$135,812	\$0	\$135,812
												535210	Freight-Delivery	\$0	\$0	\$0	\$0	\$0	\$42	\$0	\$27	(\$69)	\$0	(\$69)
												535520	Printing	\$0	\$0	\$0	\$79	\$79	\$0	\$0	\$0	\$79	\$0	\$79
											Overhead and Allocations	520190	Department Overhead	-\$825,149	\$0	\$0	\$0	-\$825,149	-\$687,336	\$0	\$0	(\$137,813)	\$0	(\$137,813)
												Salaries	501010	Perm Salaries-Misc-Regular	\$1,140,506	\$0	\$0	\$0	\$1,140,506	\$1,481,875	\$0	\$0	(\$341,369)	\$0
											501020		Misc-Sick Pay	\$0	\$0	\$0	\$0	\$0	\$59,320	\$0	\$0	(\$59,320)	\$0	(\$59,320)
											501040		Misc-Vacation	\$0	\$0	\$0	\$0	\$0	\$60,738	\$0	\$0	(\$60,738)	\$0	(\$60,738)
											501050		Misc-Other Timeoff	\$0	\$0	\$0	\$0	\$0	\$115,822	\$0	\$0	(\$115,822)	\$0	(\$115,822)
											505010		Temp Misc Regular Salaries	\$2,008	\$0	\$0	\$0	\$2,008	\$83,714	\$0	\$0	(\$81,706)	\$0	(\$81,706)
											505020		Temp Misc Sick Pay	\$0	\$0	\$0	\$0	\$0	\$7,161	\$0	\$0	(\$7,161)	\$0	(\$7,161)
											505040		Temp Misc Vacation	\$0	\$0	\$0	\$0	\$0	\$3,869	\$0	\$0	(\$3,869)	\$0	(\$3,869)
											505050		Temp Misc Other Timeoff	\$0	\$0	\$0	\$0	\$0	\$2,611	\$0	\$0	(\$2,611)	\$0	(\$2,611)
											505070		Temp Misc Holiday Pay	\$0	\$0	\$0	\$0	\$0	\$4,312	\$0	\$0	(\$4,312)	\$0	(\$4,312)
											509010		Premium Pay - Misc	\$1,982	\$0	\$0	\$0	\$1,982	\$6,726	\$0	\$0	(\$4,744)	\$0	(\$4,744)
											510010		Retroactive Salaries - Misc	\$0	\$0	\$0	\$0	\$0	\$3,244	\$0	\$0	(\$3,244)	\$0	(\$3,244)
											510210		Ret Payout - SP & Vac - Misc	\$0	\$0	\$0	\$0	\$0	\$10,355	\$0	\$0	(\$10,355)	\$0	(\$10,355)
											511010	Overtime - Scheduled Misc	\$0	\$0	\$0	\$0	\$0	\$235	\$0	\$0	(\$235)	\$0	(\$235)	
											Services Of Other Depts	581067	Sr-DPW-Building Repair	\$0	\$0	\$0	\$15,500	\$15,500	\$3,289	\$0	\$0	\$12,211	\$0	\$12,211
												581820	Is-Purch-Reproduction	\$11,872	\$0	\$0	\$0	\$11,872	\$1,543	\$0	\$0	\$10,329	\$0	\$10,329
												581890	GF-Rent Paid To Real Estate	\$1,803,599	\$0	-\$1,950	\$0	\$1,801,649	\$1,656,627	\$0	\$0	\$145,022	\$0	\$145,022
10001677 Total														\$21,076,642	\$0	-\$1,950	\$93,508	\$21,168,200	\$8,110,419	\$0	\$10,671,123	\$2,386,657	\$0	\$2,386,657
Grand Total														\$21,076,642	\$0	-\$1,950	\$93,508	\$21,168,200	\$8,110,419	\$0	\$10,671,123	\$2,386,657	\$0	\$2,386,657

FDP Subaward Amendment			
Amendment No 1		Subaward No 0001148463	
Pass-Through Entity (PTE)		Subrecipient	
Fred Hutchinson Cancer Center		Entity Name City and County of San Francisco, Public H	
		Contact Email	
Fei Gao		Principal Investigator Susan Buchbinder	
Project Title Statistical Methods for Advancing HIV Prevention			
PTE/Prime Award No. 1 R01 AI177078-01		Awarding Agency National Institutes of Health (NIH)	
Cumulative Budget Period(s) (Agreement Start Date) (End Date of Latest Budget Period)		Amount Funded This Action	Total Amount of Funds Obligated to Date
Start Date: 03/01/2023 End Date: 02/28/2025		\$35,965.00	\$70,505.00
Subrecipient Cost Share ☐		Subject to FFATA ☒	Subrecipient UEI (Unique Entity Identifier - May leave blank if unchanged from prior Agreement)
Amendment(s) to Original Terms and Conditions This Amendment revises the above-referenced Subaward Agreement as follows:			
☒ Additional Budget Period Additional budget period 03/01/2024 - 02/28/2025 is hereby added to this Su			
☐ No Cost Extension			
☒ Additional Funding Additional funding in the amount of \$35,965.00 is hereby obligated to this Subaward.			
☐ Deobligation			
Carryover is Automatic Carryover is allowed across all budget periods.			
☐ Carryover Authorized			
☒ Detailed Budget/Scope of Work/Notice of Award Attached (Specify if the Budget and Scope of Work are "New", "Revised", or "Supplemental" in dropdown or "Other") A Notice of Award and Budget is incorporated by attachment to this Amendment.			
☐ Other (See Below)			
<i>For clarity: all amounts stated in this amendment are in United States Dollars.</i>			
All other terms and conditions of this Subaward Agreement remain in full force and effect.			
By an Authorized Official of PTE:		By an Authorized Official of Subrecipient	
Date 5/21/2024		Date 05/17/2024	
Name Alexandria Nagel		Name Grant Colfax, MD	
Title Sponsored Research Officer, Office of Sp		Title Director of Health	

Approved as to form, David Chiu, City Attorney

By: **Henry Liffon**
DocuSigned by: Henry Liffon 6D6C856424584B1...

Attachment 1
Revised Budget
Subaward No:

Category	Previous Funding		Amendment #	Current Funding	
Direct Labor	\$	20,370.00	\$	21,210.00	\$ 41,580.00
Fringe Benefits		7,333.00		7,636.00	14,969.00
Subcontracts		0.00		0.00	0.00
Consultants		0.00		0.00	0.00
Capital Equipment		0.00		0.00	0.00
Patient Care		0.00		0.00	0.00
Tuition		0.00		0.00	0.00
Supplies		0.00		0.00	0.00
Travel		0.00		0.00	0.00
Other Direct Costs		0.00		0.00	0.00
Total Direct Costs	\$	27,703.00	\$	28,846.00	\$ 56,549.00
F&A		6,837.00		7,119.00	13,956.00
Total Costs	\$	34,540.00	\$	35, 965.00	\$70,505.00
F&A Rate	24.68 %				

Attachment 3B

Subaward Number:

**Research Subaward Agreement
Subrecipient Contacts****Subrecipient Information for FFATA reporting**Entity's UEI/DUNS Name: **City and County of San Francisco, Public Health Department**EIN No.: **94-6000417** Institution Type: **County Government**UEI / DUNS: **DCTNHRGU1K75** Currently registered in SAM.gov: ☒ Yes ☐ NoParent UEI / DUNS: Exempt from reporting executive compensation: Yes ☒ No ☐
(if no, complete 3B pg2)**Place of Performance Information for FFATA reporting**

Physical Address, City, State (if U.S.) and Country:

25 Van Ness, Suite 500, San Francisco, CA 94102**U.S. Entities only (insert information for Place of Performance):**Congressional District: **CA-11** Zip Code+4: **94102-4505**[Zip Code Look-up](#)**Subrecipient Contacts**Central Email: Website: Principal Investigator Name: **Susan Buchbinder**Email: Telephone Number: Administrative Contact Name: **Brett Poe**Email: Telephone Number: Financial Contact Name: **Sajid Shaikh**Email: Telephone Number: Invoice Email: Authorized Official Name: **Naveena Bobba**Email: Telephone Number: **Legal Address:****101 Grove Street
San Francisco, CA 94103****Administrative Address:****1380 Howard Street, 4th Floor
San Francisco, CA 94103****Payment Address:****1380 Howard Street, 4th Floor
San Francisco, CA 94103**

Attachment 3B Page 2
Research Subaward Agreement
Highest Compensated Officers

Subaward Number:

Subrecipient

Entity Name:

PI Name:

Highest Compensated Officers

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:

Officer 1 Compensation:

Officer 2 Name:

Officer 2 Compensation:

Officer 3 Name:

Officer 3 Compensation:

Officer 4 Name:

Officer 4 Compensation:

Officer 5 Name:

Officer 5 Compensation:




Department of Health and Human Services
National Institutes of Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES



Notice of Award
 FAIN# R01AI177078
 Federal Award Date
 01/25/2024

Recipient Information

- 1. Recipient Name**
 FRED HUTCHINSON CANCER CENTER
 1100 FAIRVIEW AVE N
 SEATTLE, WA 98109
- 2. Congressional District of Recipient**
 07
- 3. Payment System Identifier (ID)**
 1911935159A2
- 4. Employer Identification Number (EIN)**
 911935159
- 5. Data Universal Numbering System (DUNS)**
 806433145
- 6. Recipient's Unique Entity Identifier**
 TJFZLPP6NYLG
- 7. Project Director or Principal Investigator**
 Fei Gao, PHD

- 8. Authorized Official**
 Shannon K Lysen


Federal Agency Information

- 9. Awarding Agency Contact Information**
 Nicole A Guidetti
 Grants Management Program
 NATIONAL INSTITUTE OF ALLERGY AND
 INFECTIOUS DISEASES

- 10. Program Official Contact Information**
 Misrak Gezmu
 Program Official
 NATIONAL INSTITUTE OF ALLERGY AND
 INFECTIOUS DISEASES


Federal Award Information

- 11. Award Number**
 5R01AI177078-02
- 12. Unique Federal Award Identification Number (FAIN)**
 R01AI177078
- 13. Statutory Authority**
 42 USC 241 42 CFR 52
- 14. Federal Award Project Title**
 Statistical Methods for Advancing HIV Prevention
- 15. Assistance Listing Number**
 93.855
- 16. Assistance Listing Program Title**
 Allergy and Infectious Diseases Research
- 17. Award Action Type**
 Non-Competing Continuation
- 18. Is the Award R&D?**
 Yes

Summary Federal Award Financial Information

19. Budget Period Start Date 03/01/2024 – End Date 02/28/2025	
20. Total Amount of Federal Funds Obligated by this Action	\$370,816
20 a. Direct Cost Amount	\$231,153
20 b. Indirect Cost Amount	\$139,663
21. Authorized Carryover	
22. Offset	
23. Total Amount of Federal Funds Obligated this budget period	\$370,816
24. Total Approved Cost Sharing or Matching, where applicable	\$0
25. Total Federal and Non-Federal Approved this Budget Period	\$370,816
26. Project Period Start Date 03/01/2023 – End Date 02/29/2028	
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$801,834

- 28. Authorized Treatment of Program Income**
 Additional Costs
- 29. Grants Management Officer - Signature**
 Chernay L. Rogers

30. Remarks

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.



RESEARCH
Department of Health and Human Services
National Institutes of Health

Notice of Award



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 5R01AI177078-02**Principal Investigator(s):**

Fei Gao, PHD

Award e-mailed to: [REDACTED]

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$370,816 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to FRED HUTCHINSON CANCER CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI177078. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Chernay L. Rogers
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Federal Direct Costs	\$231,153
Federal F&A Costs	\$139,663
Approved Budget	\$370,816
Total Amount of Federal Funds Authorized (Federal Share)	\$370,816
TOTAL FEDERAL AWARD AMOUNT	\$370,816
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$370,816

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
2	\$370,816	\$370,816
3	\$412,018	\$412,018
4	\$419,125	\$419,125
5	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier:	1911935159A2
Document Number:	RAI177078A
PMS Account Type:	P (Subaccount)
Fiscal Year:	2024

IC	CAN	2024	2025	2026	2027
AI	8472325	\$370,816	\$412,018	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A20 / OC: 41025 / Released: Rogers, Chernay 01/24/2024
Award Processed: 01/25/2024 12:07:57 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01AI177078-02

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 5R01AI177078-02

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final

progress report when applicable.

- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI177078. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals,

- see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
 - HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
 - For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 5R01AI177078-02

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

In accordance with the fiscal year 2024 NIAID Financial Management Plan, NIAID is funding non-competing awards at 90% of the committed amount. If the final appropriations permit, adjustments may be made to restore funds at or near the FY24 committed level. See <https://www.niaid.nih.gov/grants-contracts/financial-management-plan>.

REMINDER: This grant is funded for HIV/AIDS research. Per the NIH Revitalization Act of 1993, funds are restricted for HIV/AIDS research and cannot be re-budgeted for other purposes.

This Notice of Award (NoA) includes funds for **The City and County of San Francisco**.

Commitment overlap is not permitted, and occurs when an individual's time commitment exceeds 100 percent (i.e., 12 person months), whether or not salary support is requested. Therefore, no individual's time commitment may exceed 100 percent (i.e., 12 person months). Reductions in

NIH support due to commitment overlap must be made in accordance with NIH policy as outlined in the NIH Grants Policy Statement.

SPREADSHEET SUMMARY

AWARD NUMBER: 5R01AI177078-02

INSTITUTION: FRED HUTCHINSON CANCER CENTER

Facilities and Administrative Costs	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	76%	76%	76%	76%
F&A Cost Base 1	\$183,767	\$204,185	\$218,036	\$218,036
F&A Costs 1	\$139,663	\$155,181	\$165,707	\$165,707

FDP Subaward Amendment

Awarding AgencyNational Institutes of Health (NIH)

Amendment No2

PTE/Prime Award No.5R01AI177078-03

Subaward No0001148463

Pass-Through Entity (PTE)

Subrecipient

Fred Hutchinson Cancer Center

Entity NameCITY & COUNTY OF SAN FRANCISCO, DBA PUBLIC HEALTH DEPARTMENT

Contact Email

Fei Gao

Principal InvestigatorSusan Buchbinder

Project Title

Statistical Methods for Advancing HIV Prevention

Cumulative Budget Period(s)

(Agreement Start Date) (End Date of Latest Budget Period)

Start Date: 03/01/2023

End Date: 02/28/2026

Amount Funded This Action

\$35,327.00

Total Amount of Funds Obligated to Date

\$ 105,832.00

Subrecipient Cost Share

Subject to FFATA

Subrecipient UEI (Unique Entity Identifier - May leave blank if unchanged from prior Agreement)

Amendment(s) to Original Terms and Conditions

This Amendment revises the above-referenced Subaward Agreement as follows:

Additional Budget Period

Additional budget period 03/01/2025 - 02/28/2026 is hereby added to this Subaward.

No Cost Extension

Additional Funding

Additional funding in the amount of \$ 35,327.00 is hereby obligated to this Subaward.

Deobligation

Carryover is Automatic

Carryover is allowed across all budget periods.

Carryover Authorized

Detailed Budget/Scope of Work/Notice of Award Attached

(Specify if the Budget and Scope of Work are "New", "Revised", or "Supplemental" in dropdown or "Other")

A Notice of Award and Budget

is incorporated by attachment to this Amendment.

Other (See Below)

For clarity: all amounts stated in this amendment are in United States Dollars.

All other terms and conditions of this Subaward Agreement remain in full force and effect.

By an Authorized Official of PTE:

Date06/03/2025

NameAlexandra Nagel

Sponsored Research Officer, Office of Sponsored Research

By an Authorized Official of Subrecipient:

Date05/12/2025

NameDaniel Tsai

TitleDirector of Health

Approved as to form, David chiu, City Attorney
By:

Signed by:
Eissa Hattam Hattam

FDP Mar 2024

5:01

Attachment 1
Revised Budget

Subaward No: 0001148463

Category	Previous Funding	Amendment #	Current Funding
		2	
Direct Labor	\$ 41,580.00	\$ 22,190.00	\$ 63,770.00
Fringe Benefits	14,969.00	6,657.00	21,626.00
Subcontracts	0.00	0.00	0.00
Consultants	0.00	0.00	0.00
Capital Equipment	0.00	0.00	0.00
Patient Care	0.00	0.00	0.00
Tuition	0.00	0.00	0.00
Supplies	0.00	0.00	0.00
Travel	0.00	0.00	0.00
Other Direct Costs	0.00	0.00	0.00
Total Direct Costs	\$ 56,549.00	\$ 28,847.00	\$ 85,396.00
F&A	13,956.00	6,480.00	20,436.00
Total Costs	\$ 70,505.00	\$35,327.00	\$105,832.00
F&A Rate	24.68%	22.46	%

Attachment 3B**Research Subaward Agreement
Subrecipient Contacts**

Subaward Number:

0001148463

Subrecipient Information for FFATA reporting

Entity's UEI/DUNS Name: CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT

EIN No.: 94-6000417 Institution Type: County Government

UEI / DUNS: DCTNHRGU1K75 Currently registered in SAM.gov: ☒ Yes ☐ NoParent UEI / DUNS: Exempt from reporting executive compensation: Yes ☒ No ☐
(if no, complete 3B pg2)**Place of Performance Information for FFATA reporting**

Physical Address, City, State (if U.S.) and Country:

25 Van Ness, Suite 500, San Francisco, CA 94102

U.S. Entities only (insert information for Place of Performance):

Congressional District: CA-11 Zip Code+4: 94102-4505

[Zip Code Look-up](#)**Subrecipient Contacts**

Central Email:

Website:

Principal Investigator Name: Susan Buchbinder

Email:

Telephone Number:

Administrative Contact Name: Brett Poe

Email:

Telephone Number:

Financial Contact Name: Sajid Shaikh

Email:

Telephone Number:

Invoice Email:

Authorized Official Name: Susan Philip

Email:

Telephone Number:

Legal Address:

101 Grove Street San Francisco, CA 94103

Administrative Address:

1380 Howard St, 4th Floor San Francisco, CA 94103

Payment Address:

1380 Howard St, 4th Floor San Francisco, CA 94103

Attachment 3B Page 2
Research Subaward Agreement
Highest Compensated Officers

Subaward Number:

0001148463

Subrecipient

Entity Name: CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT

PI Name: Susan Buchbinder

Highest Compensated Officers

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:

Officer 1 Compensation:

Officer 2 Name:

Officer 2 Compensation:

Officer 3 Name:

Officer 3 Compensation:

Officer 4 Name:

Officer 4 Compensation:

Officer 5 Name:

Officer 5 Compensation:



National Institutes of Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Notice of Award
FAIN# R01AI177078
Federal Award Date
04/25/2025

Recipient Information

1. Recipient Name

FRED HUTCHINSON CANCER CENTER
1100 FAIRVIEW AVE N
SEATTLE, WA 98109

2. Congressional District of Recipient

07

3. Payment System Identifier (ID)

1911935159A2

4. Employer Identification Number (EIN)

911935159

5. Data Universal Numbering System (DUNS)

806433145

6. Recipient's Unique Entity Identifier

TJFZLPP6NYL6

7. Project Director or Principal Investigator

Fei Gao, PHD

8. Authorized Official

Shannon K Lysen

Federal Agency Information

9. Awarding Agency Contact Information

Madea J. Marinik
Contract Grants Management Specialist
NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES

10. Program Official Contact Information

Misrak Gezmu
Program Official
NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES

Federal Award Information

11. Award Number

5R01AI177078-03

12. Unique Federal Award Identification Number (FAIN)

R01AI177078

13. Statutory Authority

42 USC 241 42 CFR 52

14. Federal Award Project Title

Statistical Methods for Advancing HIV Prevention

15. Assistance Listing Number

93.855

16. Assistance Listing Program Title

Allergy and Infectious Diseases Research

17. Award Action Type

Non-Competing Continuation

18. Is the Award R&D?

Yes

Summary Federal Award Financial Information

19. Budget Period Start Date 03/01/2025 – End Date 02/28/2026

20. Total Amount of Federal Funds Obligated by this Action	\$412,018
20 a. Direct Cost Amount	\$256,837
20 b. Indirect Cost Amount	\$155,181
21. Authorized Carryover	\$0
22. Offset	\$0
23. Total Amount of Federal Funds Obligated this budget period	\$412,018
24. Total Approved Cost Sharing or Matching, where applicable	\$0
25. Total Federal and Non-Federal Approved this Budget Period	\$412,018

26. Project Period Start Date 03/01/2023 – End Date 02/29/2028

27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$1,255,054
--	-------------

28. Authorized Treatment of Program Income

Additional Costs

29. Grants Management Officer - Signature

RACINE ANN MARIE Allen

30. Remarks

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.



RESEARCH
Department of Health and Human Services
National Institutes of Health

Notice of Award



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 5R01AI177078-03

Principal Investigator(s):

Fei Gao, PHD

Award e-mailed to: [REDACTED]

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$412,018 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to FRED HUTCHINSON CANCER CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI177078. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

RACINE ANN-MARIE Allen
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Federal Direct Costs	\$256,837
Federal F&A Costs	\$155,181
Approved Budget	\$412,018
Total Amount of Federal Funds Authorized (Federal Share)	\$412,018
TOTAL FEDERAL AWARD AMOUNT	\$412,018
 AMOUNT OF THIS ACTION (FEDERAL SHARE)	 \$412,018

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
3	\$412,018	\$412,018
4	\$419,125	\$419,125
5	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1911935159A2
Document Number: RA1177078A
PMS Account Type: P (Subaccount)
Fiscal Year: 2025

IC	CAN	2025	2026	2027
AI	8472325	\$412,018	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A20 / **OC:** 41025 / **Released:** 04/25/2025
Award Processed: 04/28/2025 07:11:23 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01AI177078-03

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 5R01AI177078-03

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than

the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI177078. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year

period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

Recipient is compliant with Title IX of the Education Amendments of 1972, as amended, 20 U.S.C. §§ 1681 et seq., including the requirements set forth in Presidential Executive Order 14168 titled Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government, and Title VI of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000d et seq., and Recipient will remain compliant for the duration of the Agreement.

- The above requirements are conditions of payment that go the essence of the Agreement and are therefore material terms of the Agreement.
- Payments under the Agreement are predicated on compliance with the above requirements, and therefore Recipient is not eligible for funding under the Agreement or to retain any funding under the Agreement absent compliance with the above requirements.
- Recipient acknowledges that this certification reflects a change in the government’s position regarding the materiality of the foregoing requirements and therefore any prior payment of similar claims does not reflect the materiality of the foregoing requirements to this Agreement.
- Recipient acknowledges that a knowing false statement relating to Recipient’s compliance with the above requirements and/or eligibility for the Agreement may subject Recipient to liability under the False Claims Act, 31 U.S.C. § 3729, and/or criminal liability, including under 18 U.S.C. §§ 287 and 1001.

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 5R01AI177078-03

Clinical Trial Indicator: No
This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

This award is issued in accordance with request dated 02/13/2025, notifying NIAID of Dr. Fei Gao return from sabbatical/extended leave. This NoA also reflects the removal of Dr. Holly James as interim PI.

Commitment overlap is not permitted, and occurs when an individual’s time commitment exceeds 100 percent (i.e., 12 person months), whether or not salary support is requested. Therefore, no individual’s time commitment may exceed 100 percent (i.e., 12 person months). Reductions in NIH support due to commitment overlap must be made in accordance with NIH policy as outlined in the NIH Grants Policy Statement.

REMINDER: This grant is funded for HIV/AIDS research. Per the NIH Revitalization Act of 1993, funds are restricted for HIV/AIDS research and cannot be re-budgeted for other purposes.


This Notice of Award (NoA) includes funds for City and County of San Francisco.

SPREADSHEET SUMMARY
AWARD NUMBER: 5R01AI177078-03

INSTITUTION: FRED HUTCHINSON CANCER CENTER

Facilities and Administrative	Year 3	Year 4	Year 5
-------------------------------	--------	--------	--------

Costs			
F&A Cost Rate 1	76%	76%	76%
F&A Cost Base 1	\$204,185	\$218,036	\$218,036
F&A Costs 1	\$155,181	\$165,707	\$165,707

FDP Cost Reimbursement Subaward			
Federal Awarding Agency: National Institutes of Health (NIH)			
Pass-Through Entity (PTE):		Subrecipient:	
Fred Hutchinson Cancer Center		CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT	
PTE PI: Fei Gao		Sub PI: Susan Buchbinder	
PTE Federal Award No: 1 R01 AI177078-01		Subaward No: 0001148463	
Project Title: Statistical Methods for Advancing HIV Prevention			
Subaward Budget Period:		Amount Funded This Action (USD): \$34,540.00	
Start: 03/01/2023 End: 02/29/2024			
Estimated Period of Performance:		Incrementally Estimated Total (USD): \$138,160.00	
Start: 03/01/2023 End: 02/29/2028			
Terms and Conditions			
1. PTE hereby awards a cost reimbursable subaward, (as determined by 2 CFR 200.331), to Subrecipient. The Statement of Work and budget for this Subaward are as shown in Attachment 5. In its performance of Subaward work, Subrecipient shall be an independent entity and not an employee or agent of PTE. 2. Subrecipient shall submit invoices not more often than monthly and not less frequently than quarterly for allowable costs incurred. Upon the receipt of proper invoices, the PTE agrees to process payments in accordance with this Subaward and 2 CFR 200.305. All invoices shall be submitted using Subrecipient's standard invoice, but at a minimum shall include current and cumulative costs (including cost sharing), breakdown by major cost category, Subaward number, and certification, as required in 2 CFR 200.415(a). Invoices that do not reference PTE Subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments shall be directed to the party's <u>Financial</u> Contact, shown in Attachment 3A. 3. A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be submitted to PTE's <u>Financial</u> Contact, as shown in Attachment 3A, not later than 60 days after each Budget Period end date. The final statement of costs shall constitute Subrecipient's final financial report. 4. All payments shall be considered provisional and are subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient. 5. Matters concerning the technical performance of this Subaward shall be directed to the appropriate party's Principal Investigator as shown in Attachments 3A and 3B. Technical reports are required as shown in Attachment 4. 6. Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this Subaward, and any changes requiring prior approval, shall be directed to the PTE's <u>Authorized Official</u> Contact and the Subrecipient's <u>Authorized Official</u> Contact shown in Attachments 3A and 3B. Any such change made to this Subaward requires the written approval of each party's Authorized Official as shown in Attachments 3A and 3B. 7. The PTE may issue non-substantive changes to the Budget Period(s) and Budget <u>Bilaterally</u>. Unilateral modification shall be considered valid 14 days after receipt unless otherwise indicated by Subrecipient when sent to Subrecipient's <u>Authorized Official</u> Contact, as shown in Attachment 3B. 8. Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law. 9. Either party may terminate this Subaward with 30 days written notice. Notwithstanding, if the Awarding Agency terminates the <u>Federal Award</u>, PTE will terminate in accordance with Awarding Agency requirements. PTE notice shall be directed to the <u>Authorized Official</u> Contact, and Subrecipient notice shall be directed to the <u>Authorized Official</u> Contact as shown in Attachments 3A and 3B. PTE shall pay Subrecipient for termination costs as allowable under Uniform Guidance, 2 CFR 200, or 45 CFR Part 75 Appendix IX, as applicable. 10. By signing this Subaward, including the attachments hereto which are hereby incorporated by reference, Subrecipient certifies that it will perform the Statement of Work in accordance with the terms and conditions of this Subaward and the applicable terms of the Federal Award, including the appropriate Research Terms and Conditions ("RTCs") of the Federal Awarding Agency, as referenced in Attachment 2. The parties further agree that they intend this subaward to comply with all applicable laws, regulations, and requirements.			
By an Authorized Official of the PTE:		By an Authorized Official of the Subrecipient:	
 6/8/2023		 6/7/2023	
Name: Alexandria Nagel Title: Sponsored Research Officer, Office of Sponsored Research		Name: Grant Colfax, MD Title: Director of Health	

Approved as to form, David Chiu, City Attorney

Attachment 1

Certifications and Assurances

Subaward Number:

0001148463

Certification Regarding Lobbying (2 CFR 200.450)

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief, that no Federal appropriated funds have been paid or will be paid, by or on behalf of the Subrecipient, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any Federal contract, the making of any Federal grant, the making of any Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal contract, grant, loan, or cooperative agreement in accordance with 2 CFR 200.450.

If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or intending to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the Subrecipient shall complete and submit Standard Form -LLL, "Disclosure Form to Report Lobbying," to the PTE.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by 31 U.S.C. 1352. Any person who fails to file the required certification shall be subject to a civil penalty of not less than \$10,000 and not more than \$100,000 for each such failure.

Debarment, Suspension, and Other Responsibility Matters (2 CFR 200.214 and 2 CFR 180)

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief that neither the Subrecipient nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from participation in this transaction by any federal department or agency, in accordance with 2 CFR 200.213 and 2 CFR 180.

Audit and Access to Records

Subrecipient certifies that it will provide PTE with notice of any adverse findings which impact this Subaward. Subrecipient certifies compliance with applicable provisions of 2 CFR 200.501-200.521. If Subrecipient is not required to have a Single Audit as defined by 200.501, Awarding Agency requirements, or the Single Audit Act, then Subrecipient will provide notice of the completion of any required audits and will provide access to such audits upon request. Subrecipient will provide access to records as required by parts 2 CFR 200.337 and 200.338 as applicable.

Program for Enhancement of Contractor Employee Protections (41 U.S.C 4712)

Subrecipient is hereby notified that they are required to: inform their employees working on any federal award that they are subject to the whistleblower rights and remedies of the program; inform their employees in writing of employee whistleblower protections under 41 U.S.C §4712 in the predominant native language of the workforce; and include such requirements in any agreement made with a subcontractor or subgrantee.

The Subrecipient shall require that the language of the certifications above in this Attachment 1 be included in the award documents for all subawards at all tiers (including subcontracts, subgrants, and contracts under grants, loans, and cooperative agreements) and that all subrecipients shall certify and disclose accordingly.

Use of Name

Neither party shall use the other party's name, trademarks, or other logos in any publicity, advertising, or news release without the prior written approval of an authorized representative of that party. The parties agree that each party may use factual information regarding the existence and purpose of the relationship that is the subject of this Subaward for legitimate business purposes, to satisfy any reporting and funding obligations, or as required by applicable law or regulation without written permission from the other party. In any such statement, the relationship of the parties shall be accurately and appropriately described.

Prohibition on Certain Telecommunication and Video Surveillance Services or Equipment

Pursuant to 2 CFR 200.216, Subrecipient will not obligate or expend funds received under this Subaward to: (1) procure or obtain; (2) extend or renew a contract to procure or obtain; or (3) enter into a contract (or extend or renew a contract) to procure or obtain equipment, services, or systems that uses covered telecommunications equipment or services (as described in Public Law 115-232, section 889) as a substantial or essential component of any system, or as a critical technology as part of any system.

Attachment 2

Federal Award Terms and Conditions

Subaward Number

0001148463

Required Data Elements

The data elements required by Uniform
Guidance are incorporated in the attached Federal Award.

Awarding Agency Institute (If Applicable)

Federal Award Issue Date	FAIN	Assistance Listing No.
03/01/2023	R01AI177078	93.855

This Subaward Is:

☒ Research & Development ☐ Subject to FFATA

Assistance Listing Program Title (ALPT)
Allergy and Infectious Diseases Research
Key Personnel Per NOA

General Terms and Conditions

By signing this Subaward, Subrecipient agrees to the following:

1. To abide by the conditions on activities and restrictions on expenditure of federal funds in appropriations acts that are applicable to this Subaward to the extent those restrictions are pertinent. This includes any recent legislation noted on the Federal Awarding Agency's website:

<http://grants.nih.gov/policy/notices.htm>

2. 2 CFR 200 and 45 CFR Part 75.

3. The Federal Awarding Agency's grants policy guidance, including addenda in effect as of the beginning date of the period of performance or as amended found at:

<http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>

4. Research Terms and Conditions, including any Federal Awarding Agency's Specific Requirements found at:

<https://www.nsf.gov/awards/managing/rtc.jsp>

except for the following :

- a. No-cost extensions require the written approval of the PTE. Any requests for a no-cost extension shall be directed to the Administrative Contact shown in Attachment 3A, not less than 30 days prior to the desired effective date of the requested change.
- b. Any payment mechanisms and financial reporting requirements described in the applicable Federal Awarding Agency Terms and Conditions and Agency-Specific Requirements are replaced with Terms and Conditions (1) through (4) of this Subaward; and
- c. Any prior approvals are to be sought from the PTE and not the Federal Awarding Agency.
- d. Title to equipment as defined in 2 CFR 200.1 that is purchased or fabricated with research funds or Subrecipient cost sharing funds, as direct costs of the project or program, shall vest in the Subrecipient subject to the conditions specified in 2 CFR 200.313.
- e. Prior approval must be sought for a change in Subrecipient PI or change in Key Personnel (defined as listed on the NOA).

5. Treatment of program income: Additive

Special Terms and Conditions:**Data Sharing and Access:**

Subrecipient agrees to comply with the Federal Awarding Agency's data sharing and/or access requirements as reflected in the NOA or the Federal Awarding Agency's standard terms and conditions as referenced in General Terms and Conditions 1-4 above.

No additional requirements

Data Rights:

Subrecipient grants to PTE the right to use data created in the performance of this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

Copyrights:

Subrecipient Shall Grant to PTE an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly any copyrights or copyrighted material (including any computer software and its documentation and/or databases) first developed and delivered under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its PTE Federal Award.

Subrecipient grants to PTE the right to use any written progress reports and deliverables created under this Subaward solely for the purpose of and only to the extent required to meet PTE's obligations to the Federal Government under its Federal Award.

Promoting Objectivity in Research (COI):

Subrecipient must designate herein which entity's Financial Conflicts of Interest policy (COI) will apply: Subrecipient

If applying its own COI policy, by execution of this Subaward, Subrecipient certifies that its policy complies with the requirements of the relevant Federal Awarding Agency as identified herein: NIH - 42 CFR Part 50 Subpart F

Subrecipient shall report any financial conflict of interest to PTE's Administrative Representative or COI contact, as designated on Attachment 3A. Any financial conflicts of interest identified shall, when applicable, subsequently be reported to Federal Awarding Agency. Such report shall be made before expenditure of funds authorized in this Subaward and within 45 days of any subsequently identified COI.

Work Involving Human or Vertebrate Animals (Select Applicable Options)

☒ No Human or Vertebrate Animals

This section left intentionally blank.

Human Subjects Data (Select One)

This section left intentionally blank

NIH Terms and Conditions

The Clinical Trial Indicator in Section IV of the PTE's NOA is stated as:

Multiple PIs (MPI)

Certificate of Confidentiality:

The Parties agree that this research funded in whole or in part by the National Institutes of Health ("NIH"), is subject to NIH Policy NOT-OD-17-109 (the "Policy") and therefore is deemed under the Policy to be issued a Certificate of Confidentiality ("Certificate") should the conditions outlined within the Policy apply. Accordingly, the subrecipients who collect or receive identifiable, sensitive information are required to adhere to the Policy and protect the privacy of individuals who are subjects of such research in accordance with the Policy and subsection 301(d) of the Public Health Service Act (the "PHS Act").

Additional Terms

Consortium Agreement. Subrecipient may not transfer any funds issued under this Subaward to another organization for the purposes of carrying out any portion of the planned programmatic activities in the form of a Consortium Agreement. A Consortium Agreement is a formalized agreement whereby a research project is carried out by the grantee and one or more other organizations that are separate legal entities. The referenced section of the NIH Grants Policy Statement is available at:
https://grants.nih.gov/grants/policy/nihgps/HTML5/section_15/15_consortium_agreements.htm#

Attachment 3A**Research Subaward Agreement
Pass-Through Entity (PTE) Contacts**

Subaward Number:

0001148463

PTE Information

Entity Name: Fred Hutchinson Cancer Center

Legal Address: 1100 Fairview Ave N
Seattle, WA 98109

Website: www.fredhutch.org

PTE Contacts

Central Email: [REDACTED]

Principal Investigator Name: Fei Gao

Email: [REDACTED]

Telephone Number: [REDACTED]

Administrative Contact Name: Alexandria Nagel

Email: [REDACTED]

Telephone Number: [REDACTED]

COI Contact email (if different to above): [REDACTED]

Financial Contact Name: Accounts Payable

Email: [REDACTED]

Telephone Number: [REDACTED]

Email invoices? ☒ Yes ☐ No Invoice email (if different): [REDACTED]

Authorized Official Name: Shannon K. Lysen

Email: [REDACTED]

Telephone Number: [REDACTED]

PI Address:FRED HUTCHINSON CANCER CENTER
1100 Fairview Ave N
Seattle, WA 98109**Administrative Address:**FRED HUTCHINSON CANCER CENTER
1100 Fairview Ave N
Mail Stop J6-500
Seattle, WA 98109**Invoice Address:**FRED HUTCHINSON CANCER CENTER
1100 Fairview Ave N
Mail Stop J4-500
Seattle, WA 98109

Attachment 3B**Research Subaward Agreement
Subrecipient Contacts**

Subaward Number:

0001148463

Subrecipient Information for FFATA reporting

Entity's UEI/DUNS Name: CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT

EIN No.: 94-6000417 Institution Type: County Government

UEI / DUNS: DCTNHRGU1K75 Currently registered in SAM.gov: ☒ Yes ☐ NoParent UEI / DUNS: Exempt from reporting executive compensation: Yes ☒ No ☐
(if no, complete 3B pg2)**Place of Performance Information for FFATA reporting**

Physical Address, City, State (if U.S.) and Country:

25 Van Ness, Suite 500
San Francisco, CA 94102**U.S. Entities only (insert information for Place of Performance):**

Congressional District: CA-12 Zip Code+4: 94102-4505

[Zip Code Look-up](#)**Subrecipient Contacts**

Central Email:

Website:

Principal Investigator Name: Susan Buchbinder

Email:

Telephone Number:

Administrative Contact Name: Eduardo Sida

Email:

Telephone Number:

Financial Contact Name: Sajid Shaikh

Email:

Telephone Number:

Invoice Email:

Authorized Official Name: Greg Wagner

Email:

Telephone Number:

Legal Address:101 Grove Street
San Francisco, CA 94103**Administrative Address:**1380 Howard Street, 4th Floor
San Francisco, CA 94103**Payment Address:**1380 Howard Street, 4th Floor
San Francisco, CA 94103

Attachment 3B-2
Highest Compensated Officers

Subaward Number:

0001148463

Subrecipient:

Institution Name: CITY & COUNTY OF SAN FRANCISCO; DBA PUBLIC HEALTH DEPARTMENT

PI Name: Susan Buchbinder

Highest Compensated Officers

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:

Officer 1 Compensation:

Officer 2 Name:

Officer 2 Compensation:

Officer 3 Name:

Officer 3 Compensation:

Officer 4 Name:

Officer 4 Compensation:

Officer 5 Name:

Officer 5 Compensation:

Attachment 4
Reporting and Prior Approval Terms

Subaward Number:

0001148463

Subrecipient agrees to submit the following reports (PTE contacts are identified in Attachment 3A):

Technical Reports:

- ☐ Monthly technical/progress reports will be submitted to the PTE's Administrative Contact within 30 days of the end of the month.
- ☐ Quarterly technical/progress reports will be submitted within 30 days after the end of each project quarter to the PTE's Administrative Contact.
- ☒ Annual technical / progress reports will be submitted within 30 days prior to the end of each budget period to the PTE's Principal Investigator. Such report shall also include a detailed budget for the next Budget Period, updated other support for key personnel, certification of appropriate education in the conduct of human subject research of any new key personnel, and annual IRB or IACUC approval, if applicable.
- ☒ A Final technical/progress report will be submitted to the PTE's Principal Investigator within 60 days of the end of the Project Period or after termination of this award, whichever comes first.
- ☒ Technical/progress reports on the project as may be required by PTE's Principal Investigator in order for the PTE to satisfy its reporting obligations to the Federal Awarding Agency.

Prior Approvals:

Carryover:

Carryover is automatic**Other Reports:**

- ☒ In accordance with 37 CFR 401.14, Subrecipient agrees to notify both the Federal Awarding Agency via iEdison and PTE's Administrative Contact within 60 days after Subrecipient's inventor discloses invention(s) in writing to Subrecipient's personnel responsible for patent matters. The Subrecipient will submit a final invention report using Federal Awarding Agency specific forms to the PTE's Administrative Contact within 60 days of the end of the Project Period to be included as part of the PTE's final invention report to the Federal Awarding Agency.

A negative report is required: No

- ☐ Property Inventory Report (only when required by Federal Awarding Agency), specific requirements below.

Additional Technical and Reporting Requirements:

Attachment 5
Statement of Work, Cost Sharing, Indirects & Budget

Subaward Number:

0001148463

Statement of Work

☒ Below ☐ Attached, pages

If award is FFATA eligible and SOW exceeds 4000 characters, include a *Subrecipient Federal Award Project Description*

On this project, Dr. Buchbinder will serve as a clinical expert. She will help to identify logistical/implementation and clinical issues pertinent to evaluating HIV incidence with recency testing data (Specific Aim 1), and clinical considerations pertinent to trial design and efficacy evaluation under Specific Aim 2. She will provide collaboration and input on the application of these approaches to existing datasets. She will assist in the dissemination and application of the proposed methods to future HIV prevention trials.

Budget Information

Indirect Information Indirect Cost Rate (IDC) Applied 24.678 % Rate Type: Modified Total Direct Costs	Cost Sharing No If Yes, include Amount: \$
---	--

Budget Details ☐ Below ☒ Attached, pages

Exhibit A, Budget-Cost Reimbursement follows.

§200.332(a)(1)(viii) Total Amount of Federal Funds Obligated to the subrecipient by the pass-through entity including the current financial obligation:

\$

Budget Totals

Direct Costs	\$	27,703.00
Indirect Costs	\$	6,837.00
Total Costs	\$	34,540.00

All amounts are in United States Dollars

Exhibit A of Attachment 5

Budget – Cost Reimbursement

Category		Budget
Direct Labor	\$	20,370.00
Fringe Benefits		7,333.00
Consultants		0.00
Subcontracts		0.00
Equipment		0.00
Supplies		0.00
Patient Care		0.00
Tuition		0.00
Travel		0.00
Other		0.00
Total Direct Costs	\$	27,703.00
Indirect Costs	F&A Rate: 24.678 %	\$ 6,837.00
Total Costs	\$	34,540.00

Attachment 6

Notice of Award (NOA) and any additional documents

- ☒ The following pages include the NOA and if applicable any additional documentation referenced throughout this Subaward.
- ☐ Not incorporating the NOA or any additional documentation to this Subaward.



Department of Health and Human Services
National Institutes of Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Notice of Award
FAIN# R01AI177078
Federal Award Date
03/01/2023

Recipient Information

- 1. Recipient Name**
FRED HUTCHINSON CANCER CENTER
1100 FAIRVIEW AVE N

SEATTLE, 98109
- 2. Congressional District of Recipient**
07
- 3. Payment System Identifier (ID)**
1911935159A2
- 4. Employer Identification Number (EIN)**
911935159
- 5. Data Universal Numbering System (DUNS)**
806433145
- 6. Recipient's Unique Entity Identifier**
TJFZLPP6NYL6
- 7. Project Director or Principal Investigator**
Fei Gao, PHD

- 8. Authorized Official**
Shannon K Lysen

Federal Agency Information

- 9. Awarding Agency Contact Information**
LILIEH A Campbell
Grant Management Specialist
NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES
- 10. Program Official Contact Information**
Misrak Gezmu
Program Official
NATIONAL INSTITUTE OF ALLERGY AND
INFECTIOUS DISEASES

Federal Award Information

- 11. Award Number**
1R01AI177078-01
- 12. Unique Federal Award Identification Number (FAIN)**
R01AI177078
- 13. Statutory Authority**
42 USC 241 42 CFR 52
- 14. Federal Award Project Title**
Statistical Methods for Advancing HIV Prevention
- 15. Assistance Listing Number**
93.855
- 16. Assistance Listing Program Title**
Allergy and Infectious Diseases Research
- 17. Award Action Type**
New Competing
- 18. Is the Award R&D?**
Yes

Summary Federal Award Financial Information

19. Budget Period Start Date 03/01/2023 – End Date 02/29/2024	
20. Total Amount of Federal Funds Obligated by this Action	\$431,018
20 a. Direct Cost Amount	\$256,837
20 b. Indirect Cost Amount	\$174,181
21. Authorized Carryover	
22. Offset	
23. Total Amount of Federal Funds Obligated this budget period	\$431,018
24. Total Approved Cost Sharing or Matching, where applicable	\$0
25. Total Federal and Non-Federal Approved this Budget Period	\$431,018
26. Project Period Start Date 03/01/2023 – End Date 02/29/2028	
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$431,018

- 28. Authorized Treatment of Program Income**
Additional Costs
- 29. Grants Management Officer - Signature**
Sufiyan Saeed

30. Remarks

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.



RESEARCH
Department of Health and Human Services
National Institutes of Health

Notice of Award



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 1R01AI177078-01

Principal Investigator(s):

Fei Gao, PHD

[REDACTED]

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$431,018 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to FRED HUTCHINSON CANCER CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI177078. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Sufiyan Saeed
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Federal Direct Costs	\$256,837
Federal F&A Costs	\$174,181
Approved Budget	\$431,018
Total Amount of Federal Funds Authorized (Federal Share)	\$431,018
TOTAL FEDERAL AWARD AMOUNT	\$431,018
 AMOUNT OF THIS ACTION (FEDERAL SHARE)	 \$431,018

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$431,018	\$431,018
2	\$412,018	\$412,018
3	\$412,018	\$412,018
4	\$419,125	\$419,125
5	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1911935159A2
Document Number: RAI177078A
PMS Account Type: P (Subaccount)
Fiscal Year: 2023

IC	CAN	2023	2024	2025	2026	2027
AI	8472325	\$431,018	\$412,018	\$412,018	\$419,125	\$419,125

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A20 / **OC:** 41021 / **Released:** Saeed, Sufiyan 02/17/2023
Award Processed: 03/01/2023 12:14:26 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01AI177078-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 1R01AI177078-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy

- Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
 - f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI177078. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English

- proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
 - HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
 - For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 1R01AI177078-01

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

This is a Modular Award without direct cost categorical breakdowns in accordance with the guidelines published in the NIH Grants Policy Statement, see https://grants.nih.gov/grants/policy/nihgps/HTML5/section_13/13.5_post-award_administration.htm.

Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

This Notice of Award (NoA) includes funds for **The City and County of San Francisco**.

REMINDER: This grant is funded for HIV/AIDS research. Per the NIH Revitalization Act of 1993, funds are restricted for HIV/AIDS research and cannot be re-budgeted for other purposes.

SPREADSHEET SUMMARY

AWARD NUMBER: 1R01AI177078-01

INSTITUTION: FRED HUTCHINSON CANCER CENTER

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
TOTAL FEDERAL DC	\$256,837	\$256,837	\$256,837	\$253,418	\$253,418
TOTAL FEDERAL F&A	\$174,181	\$155,181	\$155,181	\$165,707	\$165,707
TOTAL COST	\$431,018	\$412,018	\$412,018	\$419,125	\$419,125

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	76%	76%	76%	76%	76%
F&A Cost Base 1	\$229,185	\$204,185	\$204,185	\$218,036	\$218,036
F&A Costs 1	\$174,181	\$155,181	\$155,181	\$165,707	\$165,707



City and County of San Francisco
Daniel Lurie
Mayor

San Francisco Department of Public Health

Daniel Tsai
Director of Health

Memorandum

To: Honorable Members of the Board of Supervisors

From: San Francisco Department of Public Health

Date: Thursday, July 17, 2025

RE: **Retroactivity re: Files 250725 and 250743**

These Resolutions seek authorization for the Department of Public Health (DPH) to retroactively accept and expend two grant increases in the amounts of \$105,832 and \$108,968, respectively, from the National Institutes of Health (NIH) through the Fred Hutchinson Cancer Center and Family Health International for HIV research and prevention.

File 250725: Accept and Expend Grant - Retroactive - National Institutes of Health - Fred Hutchinson Cancer Center - Statistical Methods for Advancing HIV Prevention - \$105,832 – The initial project period for this grant began on March 1, 2023. DPH has since received several increases for this grant. DPH received notice of the most recent grant increase on May 12, 2025, for a project start date of March 1, 2025. The project start date was predetermined by the grantor. Upon receiving the notice of grant increase, DPH brought the item to the Controller's Office for review on May 30, 2025. The Controller's Office reviewed and forwarded the packet to the Mayor's Office on June 23, 2025, for introduction on July 1, 2025.

File 250743: Accept and Expend Grant - Retroactive - National Institutes of Health - Family Health International - HIV Prevention Trials Network - \$108,968 - The initial project period for this grant began on April 1, 2024. DPH has since received several increases for this grant. DPH received notice of the most recent grant increase on April 17, 2025, for a project start date of March 1, 2025. The project start date was predetermined by the grantor. Upon receiving the notice of grant increase, DPH brought the item to the Controller's Office for review on June 3, 2025. The Controller's Office reviewed and forwarded the packet to the Mayor's Office on June 30, 2025, for introduction on July 8, 2025.

We respectfully request retroactive authorization for these items. Please contact Christina Chiong, SFDPH Accept & Expend Unit Manager, at christina.chiong@sfdph.org for any questions about this request for retroactive authorization.



Daniel Lurie
Mayor

TO: Angela Calvillo, Clerk of the Board of Supervisors

FROM: Daniel Tsai
Director of Health

DATE: 7/2/2025

SUBJECT: Grant Accept and Expend

GRANT TITLE: Statistical Methods for Advancing HIV Prevention -
\$105,832

Attached please find the original and 1 copy of each of the following:

- ☒ Proposed grant resolution, original signed by Department
- ☒ Grant information form, including disability checklist
- ☒ Budget and Budget Justification
- ☐ Grant application: Not Applicable. No application submitted.
- ☒ Agreement / Award Letter
- ☐ Other (Explain):

Special Timeline Requirements:

Departmental representative to receive a copy of the adopted resolution:

Name: Gregory Wong (greg.wong@sfdph.org) Phone: 554-2521

Interoffice Mail Address: Dept. of Public Health, 101 Grove St # 108

Certified copy required Yes ☐

No ☒

OFFICE OF THE MAYOR
SAN FRANCISCO



DANIEL LURIE
MAYOR

TO: Angela Calvillo, Clerk of the Board of Supervisors
FROM: Adam Thongsavat, Liaison to the Board of Supervisors
RE: Accept and Expend Grant - Retroactive - National Institutes of Health - Fred Hutchinson Cancer Center - Statistical Methods for Advancing HIV Prevention - \$105,832
DATE: July 1, 2025

Resolution retroactively authorizing the Department of Public Health to accept and expend a grant from the National Institutes of Health through Fred Hutchinson Cancer Center for participation in a program, entitled "Statistical Methods for Advancing HIV Prevention in the amount \$105,832 for the period of March 1, 2023, through February 28, 2026.

Should you have any questions, please contact Adam Thongsavat at adam.thongsavat@sfgov.org